$32.37 -0.36 (-1.10%)
2/10/2012 4:05 PM

Dr. Reddy's Laboratories Limited (ADR) (NYSE:RDY)

CAPS Rating: 4 out of 5

A global pharmaceutical company, which produces pharmaceutical ingredients and intermediates, finished dosage forms and biotechnology products and markets them globally. It conducts research in the areas of cancer, diabetes, cardiovascular disease etc.

Results 1 - 20 of 79 : 1 2 3 4 Next »

Recs

0
Member Avatar desidadda (22.53) Submitted: 12/21/2011 9:44:41 PM : Outperform Start Price: $29.91 RDY Score: +0.42

Generics rock

Recs

0
Member Avatar Omen1618 (< 20) Submitted: 10/21/2011 10:57:19 AM : Outperform Start Price: $31.50 RDY Score: -5.85

This company makes generic pharmaceuticals, ton of pharma patents coming due in the near future which provides DRL with a big upside.

Recs

0
Member Avatar dnelyo (< 20) Submitted: 9/10/2011 6:45:58 PM : Outperform Start Price: $30.49 RDY Score: -11.21

India + pharmaceuticals = general guess into demographic growth & spending

Recs

0
Member Avatar rwpaules (96.11) Submitted: 6/16/2011 4:40:35 PM : Underperform Start Price: $34.32 RDY Score: +10.71

Major FDA compliance issues going on in this company that will be costly to correct if they want to maintain access to the US market. See warning letter here:
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm258679.htm

Recs

0
Member Avatar 1derway (< 20) Submitted: 5/27/2011 2:24:54 PM : Outperform Start Price: $35.01 RDY Score: -8.18

I always buy generics! What a great company!

next 5 years eps growth 56%
peg .46!!!

Hello!

Recs

0
Member Avatar HardnoseDotCom (73.69) Submitted: 4/25/2011 1:31:30 PM : Outperform Start Price: $37.04 RDY Score: -13.17

low PEG, strong price uptrend

Recs

0
Member Avatar frederick7 (< 20) Submitted: 2/23/2011 12:38:15 PM : Outperform Start Price: $33.54 RDY Score: -6.25

Big money!

Recs

0
Member Avatar istraveler (< 20) Submitted: 12/29/2010 1:37:53 AM : Outperform Start Price: $34.24 RDY Score: -9.75

generic drugs + 7 Billion worldwide population = mega trend upside potential.

Recs

0
Member Avatar modestus1 (< 20) Submitted: 12/27/2010 10:49:56 PM : Outperform Start Price: $36.41 RDY Score: -17.82

One of India's leading generic drug maker with a large market to expand.

Recs

0
Member Avatar wombataholic (< 20) Submitted: 12/10/2010 4:34:33 PM : Underperform Start Price: $39.12 RDY Score: +24.71

Grossly overpriced.

Recs

0
Member Avatar dgoldenz (20.01) Submitted: 11/8/2010 10:35:58 AM : Outperform Start Price: $39.29 RDY Score: -27.54

up, up, and away

Recs

0
Member Avatar rogervictor (< 20) Submitted: 10/26/2010 2:16:46 PM : Outperform Start Price: $36.97 RDY Score: -25.90

With the expiration of expensive patten, generic drug manufacturers are bound to prosper. TEVA, andReddy could be the next beneficiaries.

Recs

0
Member Avatar msricekc (76.92) Submitted: 10/13/2010 11:37:57 AM : Outperform Start Price: $13.76 RDY Score: +126.84

I sold too early.

Recs

0
Member Avatar jimrusch22 (91.33) Submitted: 7/26/2010 3:53:37 PM : Outperform Start Price: $27.39 RDY Score: -2.21

rapidy growing globally - as aggressivie a company as TEVA

Recs

0
Member Avatar AmericanGenius (< 20) Submitted: 6/4/2010 11:44:38 AM : Outperform Start Price: $29.35 RDY Score: -13.52

India or Pharm? How about both!

Recs

0
Member Avatar LevGross (36.40) Submitted: 5/28/2010 9:53:01 AM : Outperform Start Price: $28.19 RDY Score: -6.96

Really like this company. Major player in generics in the US and positioned in the country with the biggest growth potential. Buy this and ABB.

Recs

0
Member Avatar sanjay1969 (< 20) Submitted: 5/28/2010 6:25:10 AM : Outperform Start Price: $28.10 RDY Score: -6.26

regarding hydrocarbon industry

Recs

0
Member Avatar tytymhorau (39.33) Submitted: 5/16/2010 4:09:09 PM : Outperform Start Price: $27.37 RDY Score: -0.28

India-based mid-cap pharmaceutical company - a global provider of generic drugs and related active ingredients. Poised to profit from an increasing pipeline of drugs coming off patent, the insurance industry's increasing push toward generics in developed countries, and the cost effectiveness of generics for expanding health care in developing countries.

Recs

1
Member Avatar NHWeston (77.46) Submitted: 4/2/2010 12:09:39 PM : Outperform Start Price: $28.31 RDY Score: +0.72

Dr. Reddy's is a rapidly growing player in the global generics market. For now, they virtually own their domestic market in India and, although overshadowed by more flashy companies like Teva, they are gaining market share in Europe and Latin America. Less celebrated but also important is - or so I'm told - they're doing some interesting original work in melanoma, diabetes, and cholera. I've also heard talk that they might be a t6ake-over candidate although the New Delhi government would pose an obstale here. 35 by Christmas. Regards.

Results 1 - 20 of 79 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement